Praxis Precision Medicines Pauses Epilepsy Drug Development After Phase 2/3 Trial Misses Primary Endpoint
Key Insights
Praxis Precision Medicines' experimental epilepsy drug vormatrigine failed to meet its primary endpoint of reducing monthly seizure frequency in the POWER1 Phase 2/3 registrational study.
The company has paused enrollment in the POWER2 study to reassess the vormatrigine program, though the drug showed encouraging signals on higher doses and maintained a solid safety profile.
Despite the setback, vormatrigine met a key secondary endpoint with a 50% responder rate and demonstrated more pronounced seizure reduction during the second half of the study.
Praxis Precision Medicines announced Monday that its experimental epilepsy drug vormatrigine failed to meet the primary endpoint in a Phase 2/3 registrational study, prompting the company to pause enrollment in a second pivotal trial while reassessing the program's future. The news sent shares plunging more than 12% in extended trading.
Trial Results and Key Findings
In the POWER1 Phase 2/3 registrational study, vormatrigine did not achieve its primary endpoint of reducing monthly seizure frequency in adults with focal onset seizures who were taking one to three anti-seizure medications. Patients were randomized to receive once-daily vormatrigine or placebo for 12 weeks.
Despite missing the primary goal, the trial demonstrated several encouraging signals. Vormatrigine met a key secondary endpoint—the 50% responder rate—indicating that a meaningful proportion of patients experienced at least a 50% reduction in seizures. Additionally, seizure reduction was more pronounced during the second half of the study, particularly in patients receiving the higher 30 mg dose.
The drug maintained a favorable safety profile throughout the trial, with adverse event-related discontinuations remaining below 10%. Vormatrigine was generally well-tolerated across the study population.
Program Reassessment and Strategic Response
Following these results, Praxis has paused enrollment in the POWER2 study to conduct a comprehensive reassessment of the vormatrigine program and evaluate potential modifications. The company has not announced immediate changes to other ongoing trials or regulatory timelines.
"While the results for POWER1 were not what we hoped for, we are encouraged by the signal we saw on the higher dose arm, the low discontinuation rate and solid safety profile," said Marcio Souza, president and chief executive officer of Praxis. "We will take some time to review these results to ensure we have the best path forward for developing vormatrigine and the ongoing POWER2 study."
Drug Profile and Mechanism
Vormatrigine is a once-daily oral therapy designed to target hyperexcitable sodium channels in the brain. The drug has been considered a key pipeline asset alongside Praxis's more advanced candidates relutrigine and ulixacaltamide. The POWER1 trial specifically studied the drug's safety and efficacy in adults with focal onset seizures, a type of epilepsy where seizures begin in one part of the brain.
Analyst Perspective and Market Impact
Piper Sandler analyst Yasmeen Rahimi noted that investors had not been giving much credit to this asset, suggesting the market impact may be limited. She characterized the decision to pause enrollment in the second study as the "right call" given the mixed results.
Despite the vormatrigine setback, Praxis reiterated that it remains on track with preparations for commercial launches of its other late-stage candidates while continuing to advance its broader precision neuroscience pipeline. The company's focus on precision medicine approaches to neurological disorders continues with its other programs moving forward as planned.